RM-718 vs setmelanotide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: MC4R · full Obesity pipeline

RM-718

Developed by Rhythm Pharmaceuticals

Phase 1/2 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT06239116 (registry estimate)

No aligned efficacy figure on record for this race.

setmelanotide · Imcivree

Marketed by Rhythm Pharmaceuticals

Approved in Obesitypeptide
Weak signal

NCT02896192 · Phase 3 · completed

The study was an open-label, single-group trial of 15 participants; although it included a short double-blind placebo-withdrawal period, the primary one-year weight-loss endpoint was assessed without a parallel placebo or active-control arm. The primary endpoint was statistically positive against a predefined 5% benchmark, but the uncontrolled design limits the strength of evidence.

Next expected readout: March 2027 · NCT06760546 (registry estimate)

Reported efficacy

Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) (met)

Result source: NCT05774756

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRM-718setmelanotide
Body weight, % change—Not reported0.4% vs -0.4%+0.8 vs placebo2.5 mg · wk 6 · n 9NCT02311673
20 other results
  • -2.3% vs -0.1% 2 mg QD · wk 12 · n 22 · Phase 1/2 · primary NCT02041195
  • -0.8% vs -0.4% 1.5 mg · wk 6 · n 12 · Phase 2 · primary NCT02311673
  • -2% vs -0.3% wk 12.857 · n 33 · Phase 2 · primary NCT01749137
  • -0.7% vs 2.9% 1.5 mg QD · wk 12 · n 6 · Phase 1/2 · primary NCT02041195
  • -1.3% vs 2.3% 1.5 mg QD · wk 12 · n 10 · Phase 1/2 · primary NCT02041195
  • -1.4% vs 2.9% 0.75 mg BID · wk 12 · n 8 · Phase 1/2 · primary NCT02041195
  • -0.7% vs -0.4% 0.5 mg · wk 6 · n 4 · Phase 2 · primary NCT02311673
  • 0% vs 0.2% 2.5 mg · wk 8 · n 5 · Phase 2 · secondary NCT02311673
  • 0.9% vs -1% 2.5 mg · wk 8 · n 4 · Phase 2 · secondary NCT02311673
  • 0.7% vs -0.7% 2.5 mg · wk 6 · n 4 · Phase 2 · secondary NCT02311673
  • -0.3% vs -0.9% 2.5 mg · wk 6 · n 8 · Phase 2 · secondary NCT02311673
  • 0% vs 0.2% 1.5 mg · wk 8 · n 10 · Phase 2 · secondary NCT02311673
  • -0.4% vs -1% 1.5 mg · wk 8 · n 6 · Phase 2 · secondary NCT02311673
  • -0.5% vs -0.7% 1.5 mg · wk 6 · n 6 · Phase 2 · secondary NCT02311673
  • -1.1% vs -0.9% 1.5 mg · wk 6 · n 12 · Phase 2 · secondary NCT02311673
  • -2.3% vs -0.7% wk 12.857 · n 17 · Phase 2 · secondary NCT01749137
  • 1.3% vs 0.2% 0.5 mg · wk 8 · n 3 · Phase 2 · secondary NCT02311673
  • 0.2% vs -1% 0.5 mg · wk 8 · n 2 · Phase 2 · secondary NCT02311673
  • -0.7% vs -0.7% 0.5 mg · wk 6 · n 2 · Phase 2 · secondary NCT02311673
  • -0.2% vs -0.9% 0.5 mg · wk 6 · n 4 · Phase 2 · secondary NCT02311673
Weight loss of 5% or more—Not reported9.1% vs 5.6%+3.5 vs placebowk 12.857 · n 33NCT01749137
1 other result
  • 11.8% vs 11.8% wk 12.857 · n 17 · Phase 2 · secondary NCT01749137
Weight loss of 10% or more—Not reported—Not posted · NCT06596135
Waist circumference, change (cm)—Not reported—Not posted · NCT06596135

Body weight, % change

RM-718
—Not reported
setmelanotide
0.4% vs -0.4%+0.8 vs placebo2.5 mg · wk 6 · n 9NCT02311673
20 other results
  • -2.3% vs -0.1% 2 mg QD · wk 12 · n 22 · Phase 1/2 · primary NCT02041195
  • -0.8% vs -0.4% 1.5 mg · wk 6 · n 12 · Phase 2 · primary NCT02311673
  • -2% vs -0.3% wk 12.857 · n 33 · Phase 2 · primary NCT01749137
  • -0.7% vs 2.9% 1.5 mg QD · wk 12 · n 6 · Phase 1/2 · primary NCT02041195
  • -1.3% vs 2.3% 1.5 mg QD · wk 12 · n 10 · Phase 1/2 · primary NCT02041195
  • -1.4% vs 2.9% 0.75 mg BID · wk 12 · n 8 · Phase 1/2 · primary NCT02041195
  • -0.7% vs -0.4% 0.5 mg · wk 6 · n 4 · Phase 2 · primary NCT02311673
  • 0% vs 0.2% 2.5 mg · wk 8 · n 5 · Phase 2 · secondary NCT02311673
  • 0.9% vs -1% 2.5 mg · wk 8 · n 4 · Phase 2 · secondary NCT02311673
  • 0.7% vs -0.7% 2.5 mg · wk 6 · n 4 · Phase 2 · secondary NCT02311673
  • -0.3% vs -0.9% 2.5 mg · wk 6 · n 8 · Phase 2 · secondary NCT02311673
  • 0% vs 0.2% 1.5 mg · wk 8 · n 10 · Phase 2 · secondary NCT02311673
  • -0.4% vs -1% 1.5 mg · wk 8 · n 6 · Phase 2 · secondary NCT02311673
  • -0.5% vs -0.7% 1.5 mg · wk 6 · n 6 · Phase 2 · secondary NCT02311673
  • -1.1% vs -0.9% 1.5 mg · wk 6 · n 12 · Phase 2 · secondary NCT02311673
  • -2.3% vs -0.7% wk 12.857 · n 17 · Phase 2 · secondary NCT01749137
  • 1.3% vs 0.2% 0.5 mg · wk 8 · n 3 · Phase 2 · secondary NCT02311673
  • 0.2% vs -1% 0.5 mg · wk 8 · n 2 · Phase 2 · secondary NCT02311673
  • -0.7% vs -0.7% 0.5 mg · wk 6 · n 2 · Phase 2 · secondary NCT02311673
  • -0.2% vs -0.9% 0.5 mg · wk 6 · n 4 · Phase 2 · secondary NCT02311673

Weight loss of 5% or more

RM-718
—Not reported
setmelanotide
9.1% vs 5.6%+3.5 vs placebowk 12.857 · n 33NCT01749137
1 other result
  • 11.8% vs 11.8% wk 12.857 · n 17 · Phase 2 · secondary NCT01749137

Weight loss of 10% or more

RM-718
—Not reported
setmelanotide
—Not posted · NCT06596135

Waist circumference, change (cm)

RM-718
—Not reported
setmelanotide
—Not posted · NCT06596135
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

RM-718: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. RM-718: 0 of 4 rows · setmelanotide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsetmelanotide
Dropout rate
0%a
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
0%
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
—Setmelanotide (Double-Blind Period
NCT03746522 · Phase 3
—Setmelanotide (Open-label)
NCT03746522 · Phase 3
0%Setmelanotide: BBS Group
NCT04966741 · Phase 3
14.3%Setmelanotide: PPL Group
NCT04966741 · Phase 3
56.6%
NCT03651765 · Phase 2/3 · registry result, not featured evidence
39%Stage 1: Setmelanotide (Open-Label
NCT04963231 · Phase 2 · registry result, not featured evidence
—Stage 2: Setmelanotide (Double-Bli
NCT04963231 · Phase 2 · registry result, not featured evidence
11.1%
NCT04725240 · Phase 2 · registry result, not featured evidence
0%16p11.2 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
50%AS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
30%BBS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
24.5%MC4R Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
60%POMC/PCSK1/LEPR Composite Heterozy
NCT03013543 · Phase 2 · registry result, not featured evidence
25.9%POMC/PCSK1/LEPR Compound Heterozyg
NCT03013543 · Phase 2 · registry result, not featured evidence
33.3%POMC/PCSK1/LEPR Heterozygous Cohor
NCT03013543 · Phase 2 · registry result, not featured evidence
40.9%SH2B1 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
25%SMS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
31.3%SRC1 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
40.5%
NCT01749137 · Phase 2 · registry result, not featured evidence
24.1%2 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
33.3%1.5 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
9.1%1.5 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
20%0.75 mg BID
NCT02041195 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
—
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
—Setmelanotide (Double-Blind Period
NCT03746522 · Phase 3
—Setmelanotide (Open-label)
NCT03746522 · Phase 3
—Setmelanotide: BBS Group
NCT04966741 · Phase 3
—Setmelanotide: PPL Group
NCT04966741 · Phase 3
2.9%
NCT03651765 · Phase 2/3 · registry result, not featured evidence
26.2%Stage 1: Setmelanotide (Open-Label
NCT04963231 · Phase 2 · registry result, not featured evidence
—Stage 2: Setmelanotide (Double-Bli
NCT04963231 · Phase 2 · registry result, not featured evidence
11.1%
NCT04725240 · Phase 2 · registry result, not featured evidence
0%16p11.2 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
0%AS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
0%BBS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
6.1%MC4R Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
20%POMC/PCSK1/LEPR Composite Heterozy
NCT03013543 · Phase 2 · registry result, not featured evidence
11.1%POMC/PCSK1/LEPR Compound Heterozyg
NCT03013543 · Phase 2 · registry result, not featured evidence
6.1%POMC/PCSK1/LEPR Heterozygous Cohor
NCT03013543 · Phase 2 · registry result, not featured evidence
36.4%SH2B1 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
0%SMS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
6.3%SRC1 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
10.8%
NCT01749137 · Phase 2 · registry result, not featured evidence
10.3%2 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
22.2%1.5 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
0%1.5 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
10%0.75 mg BID
NCT02041195 · Phase 1/2 · registry result, not featured evidence
Serious AEs
40%a
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
20%
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
3.7%Setmelanotide (Double-Blind Period
NCT03746522 · Phase 3
0%Setmelanotide (Open-label)
NCT03746522 · Phase 3
0%Setmelanotide: BBS Group
NCT04966741 · Phase 3
0%Setmelanotide: PPL Group
NCT04966741 · Phase 3
13.2%
NCT03651765 · Phase 2/3 · registry result, not featured evidence
3.7%Stage 1: Setmelanotide (Open-Label
NCT04963231 · Phase 2 · registry result, not featured evidence
0%Stage 2: Setmelanotide (Double-Bli
NCT04963231 · Phase 2 · registry result, not featured evidence
5.6%
NCT04725240 · Phase 2 · registry result, not featured evidence
5.3%16p11.2 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
0%AS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
10%BBS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
2%MC4R Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
20%POMC/PCSK1/LEPR Composite Heterozy
NCT03013543 · Phase 2 · registry result, not featured evidence
7.4%POMC/PCSK1/LEPR Compound Heterozyg
NCT03013543 · Phase 2 · registry result, not featured evidence
3%POMC/PCSK1/LEPR Heterozygous Cohor
NCT03013543 · Phase 2 · registry result, not featured evidence
0%SH2B1 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
0%SMS Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
0%SRC1 Cohort
NCT03013543 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%0.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
0%
NCT01749137 · Phase 2 · registry result, not featured evidence
3.4%2 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
0%1.5 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
0%1.5 mg QD
NCT02041195 · Phase 1/2 · registry result, not featured evidence
0%0.75 mg BID
NCT02041195 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
skin hyperpigmentation 100%
injection site erythema 80%
injection site oedema 60%
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 32 more results
injection site erythema 73.3%
skin hyperpigmentation 73.3%
injection site pruritus 53.3%
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
skin hyperpigmentation 63% (placebo 0%)
injection site erythema 44.4% (placebo 44%)
injection site pruritus 29.6% (placebo 36%)
NCT03746522 · Phase 3
skin hyperpigmentation 38% (placebo 0%)
nausea 16% (placebo 24%)
vomiting 16% (placebo 0%)
NCT03746522 · Phase 3
skin hyperpigmentation 80%
injection site bruising 60%
injection site pruritus 60%
NCT04966741 · Phase 3
skin hyperpigmentation 71.4%
fall 57.1%
upper respiratory tract infection 57.1%
NCT04966741 · Phase 3
skin hyperpigmentation 53.7%
covid-19 29.3%
headache 29.3%
NCT03651765 · Phase 2/3 · registry result, not featured evidence
skin hyperpigmentation 79.3% (placebo 7.1%)
nausea 45.7% (placebo 0%)
injection site erythema 37.8% (placebo 14.3%)
NCT04963231 · Phase 2 · registry result, not featured evidence
melanocytic naevus 20% (placebo 14.3%)
skin hyperpigmentation 20% (placebo 7.1%)
headache 11.4% (placebo 0%)
NCT04963231 · Phase 2 · registry result, not featured evidence
nausea 61.1%
skin hyperpigmentation 33.3%
vomiting 33.3%
NCT04725240 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 89.5%
headache 47.4%
nausea 47.4%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 75%
injection site pruritus 50%
viral upper respiratory tract infection 50%
NCT03013543 · Phase 2 · registry result, not featured evidence
injection site pruritus 90%
skin hyperpigmentation 80%
injection site oedema 70%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 81.6%
melanocytic naevus 28.6%
nausea 24.5%
NCT03013543 · Phase 2 · registry result, not featured evidence
nausea 80%
skin hyperpigmentation 60%
injection site erythema 40%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 77.8%
headache 48.1%
nausea 48.1%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 57.6%
nausea 42.4%
fatigue 33.3%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 72.7%
nausea 59.1%
headache 45.5%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 83.3%
diarrhoea 33.3%
macule 25%
NCT03013543 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 71.9%
nausea 34.4%
melanocytic naevus 25%
NCT03013543 · Phase 2 · registry result, not featured evidence
2.5 mg
injection site erythema 50% (placebo 40%)
injection site induration 25% (placebo 20%)
blood creatine phosphokinase increased 12.5% (placebo 0%)
NCT02311673 · Phase 2 · registry result, not featured evidence
2.5 mg
injection site erythema 37.5% (placebo 40%)
injection site induration 37.5% (placebo 20%)
injection site discolouration 12.5% (placebo 0%)
NCT02311673 · Phase 2 · registry result, not featured evidence
2.5 mg
injection site erythema 80% (placebo 40%)
abnormal behaviour 0% (placebo 0%)
aggression 0% (placebo 0%)
NCT02311673 · Phase 2 · registry result, not featured evidence
1.5 mg
injection site erythema 38.5% (placebo 40%)
injection site induration 30.8% (placebo 20%)
injection site pruritus 23.1% (placebo 6.7%)
NCT02311673 · Phase 2 · registry result, not featured evidence
1.5 mg
injection site erythema 36.4% (placebo 40%)
injection site induration 27.3% (placebo 20%)
injection site oedema 27.3% (placebo 13.3%)
NCT02311673 · Phase 2 · registry result, not featured evidence
1.5 mg
injection site erythema 40% (placebo 40%)
injection site induration 20% (placebo 20%)
injection site oedema 20% (placebo 13.3%)
NCT02311673 · Phase 2 · registry result, not featured evidence
0.5 mg
injection site bruising 75% (placebo 20%)
injection site erythema 75% (placebo 40%)
headache 50% (placebo 0%)
NCT02311673 · Phase 2 · registry result, not featured evidence
0.5 mg
injection site erythema 66.7% (placebo 40%)
injection site induration 66.7% (placebo 20%)
injection site bruising 33.3% (placebo 20%)
NCT02311673 · Phase 2 · registry result, not featured evidence
skin hyperpigmentation 24.3% (placebo 0%)
application site pruritus 13.5% (placebo 2.7%)
nausea 13.5% (placebo 8.1%)
NCT01749137 · Phase 2 · registry result, not featured evidence
2 mg QD
skin hyperpigmentation 89.7% (placebo 33.3%)
nausea 58.6% (placebo 0%)
headache 55.2% (placebo 0%)
NCT02041195 · Phase 1/2 · registry result, not featured evidence
1.5 mg QD
nausea 66.7% (placebo 0%)
skin hyperpigmentation 66.7% (placebo 33.3%)
headache 44.4% (placebo 0%)
NCT02041195 · Phase 1/2 · registry result, not featured evidence
1.5 mg QD
skin hyperpigmentation 72.7% (placebo 33.3%)
nausea 54.5% (placebo 0%)
headache 36.4% (placebo 0%)
NCT02041195 · Phase 1/2 · registry result, not featured evidence
0.75 mg BID
skin hyperpigmentation 70% (placebo 33.3%)
headache 50% (placebo 0%)
injection site pruritus 40% (placebo 0%)
NCT02041195 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 34 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

setmelanotide

Weight Loss 10% 80% (n=10) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
85.7% (n=14) @ 52wk
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
Weight 0% (n=20) @ 10wk2.5 mg
percent change · % of baseline
No placebo or comparator arm
NCT02311673 · Phase 2 · registry result, not featured evidence
show 13 more results
0% (n=19) @ 10wk1.5 mg
NCT02311673 · Phase 2 · registry result, not featured evidence
-25.83% (n=13) @ 52wk
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
-12.34% (n=10) @ 52wk
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
-2.19% (n=19) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-6.38% (n=4) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-4.19% (n=10) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-0.75% (n=49) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-3.5% (n=33) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-0.31% (n=5) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-5.57% (n=27) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-2.92% (n=22) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
0% (n=12) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-3.34% (n=32) @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
Hunger -27.1% (n=7) @ 52wk
percent change · % of baseline
No placebo or comparator arm
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-42.7% (n=10) @ 52wk
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
Hunger Improvement 25% 50% (n=8) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
Waist Circumference Change -17.51 cm @ 52wk
absolute change · cm
No placebo or comparator arm
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 2 more results
-9.8 cm @ 52wk
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
-10.275 cm @ 16wk
NCT04725240 · Phase 2 · registry result, not featured evidence
BMI -27.32% (n=11) @ 52wk
percent change · % of baseline
No placebo or comparator arm
NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3
show 3 more results
-14.24% (n=7) @ 52wk
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
-25.597% (n=6) @ 52wk
NCT04966741 · Phase 3
-9.719% (n=5) @ 52wk
NCT04966741 · Phase 3
Weight Loss 10 45.5% (n=11) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
53.3% (n=15) @ 52wk
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
Hunger 25 Improvement 71.4% (n=14) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3
BMI Z-Score 0.2 Reduction 85.7% (n=7) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT04966741 · Phase 3
show 1 more result
80% (n=5) @ 52wk
NCT04966741 · Phase 3
BMI Z -5.185 Z-score @ 52wk
absolute change · Z-score
No placebo or comparator arm
NCT04966741 · Phase 3
show 1 more result
-1.331 Z-score @ 52wk
NCT04966741 · Phase 3
BMI Percent of 95th Percentile -47.595% (n=6) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT04966741 · Phase 3
show 1 more result
-14.462% (n=5) @ 52wk
NCT04966741 · Phase 3
Weight -7.139 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT04966741 · Phase 3
show 11 more results
-0.327 kg @ 52wk
NCT04966741 · Phase 3
-2.58 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-5.16 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-4.61 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-1.26 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-4.74 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-0.11 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-7.24 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-3.98 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-0.14 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence
-3.96 kg @ 12wk
NCT03013543 · Phase 2 · registry result, not featured evidence

+ 32 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: RM-718's landscape · setmelanotide's landscape